The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

The mid-stage IMscin002 study showed that 71% of patients preferred Tecentriq Hybreza over IV infusion. The new SC option ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

And similar to Ocrevus Zunovo in multiple sclerosis, Roche recently received FDA approval for Tecentriq Hybreza, the subcutaneous version of the PD-L1 antibody. The growth of Tecentriq has stalled ...

Roche/Genentech’s Tecentriq represents the best value for money among the new generation of immunotherapy treatments for lung cancer – but is still overpriced. That’s the conclusion of ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

Roche/Genentech's cancer immunotherapy Tecentriq has gained FDA approval as a second line treatment for advanced lung cancer. The approval ups the ante in the non-small cell lung cancer market ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is celebrating the FDA approval of Roche's Tecentriq Hybreza™ with its drug delivery technology ENHANZE® for multiple types of cancer. Tecentriq ...

“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...